1. 2766 Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Data from the ANTHALYA trial. (September 2015) Authors: Selle, F.; Gouy, S.; Lambaudie, E.; Guyon, F.; Fourchotte, V.; Pomel, C.; Colombo, P.E.; Kalbacher, E.; Martin-Francoise, S.; Fauvet, R.; Follana, P.; Lesoin, A.; Lecuru, F.; Menguy, V.; Ghazi, Y.; Chereau, E.; Zohar, S.; Cottu, P.; Joly, F.; Rouzier, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2705 The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO): How this organization changed management over the time for rare cancers. (September 2015) Authors: Pautier, P.; Selle, F.; Devouassoux-Shisheboran, M.; Treilleux, I.; Floquet, A.; Croce, S.; Ferron, G.; Mery-Lamarche, E.; Pomel, C.; Penault-Llorca, F.; Leblanc, E.; Lefeuvre-Plesse, C.; Henno, S.; Joly, F.; Nadeau, C.; Dubois-Gordeeff, A.; Chiannilkulchai, N.; Genestie, C.; Vacher-Lavenu, M.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC). (September 2015) Authors: Oza, A.M.; Selle, F.; Davidenko, I.; Korach, J.; Mendiola, C.; Gocze, P.; Pautier, P.; Chmielowska, E.; Bamias, A.; DeCensi, A.; Zvirbule, Z.; Gonzalez-Martin, A.; Hegg, R.; Joly, F.; Zamagni, C.; Gadducci, A.; Deurloo, R.; Revil, C.; Robb, S.; Colombo, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2740 Independent review committee assessment of Fagotti carcinomatosis score from 8 laparoscopic images: Ancillary analysis of ANTHALYA, a randomized, open-label, phase II study assessing the efficacy and safety of bevacizumab addition to neoadjuvant therapy for women with ovarian, tubal or peritoneal adenocarcinoma, initially unresectable. (September 2015) Authors: Chéreau, E.; Gouy, S.; Lambaudie, E.; Ballester, M.; Fourchotte, V.; Guyon, F.; Pomel, C.; Colombo, P.E.; Delroeux, D.; Martin-Francoise, S.; Bihan, C.; Leblanc, E.; Lecuru, F.; Fouche, Y.; Ghazi, Y.; Pau, D.; Selle, F.; Cottu, P.; Joly, F.; Rouzier, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S543 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2772 Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting. (September 2015) Authors: Cottu, P.; Rouge, T. De La Motte; Pautier, P.; Provansal, M.; Floquet, A.; Selle, F.; Mouret-Reynier, M.A.; Fabbro, M.; Kalbacher, E.; Piprot, C.; Follana, P.; Lesoin, A.; Medioni, J.; Menguy, V.; Ghazi, Y.; Bidard, F.C.; Dubot, C.; Joly, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗